<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">Alcoholic Hepatitis</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="950" role="article" about="/commodorecompendium/alcoholic-hepatitis" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><div class="WordSection1">
<table class="TableGrid8" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
<tbody>
<tr>
<td style="border-bottom:1px solid black; width:100%; padding:0in 7px 0in 0in; height:12px; border-top:2px double black; border-right:none; border-left:none">
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><a name="_Hlk74038981" id="_Hlk74038981"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Alcoholic Hepatitis – Alex Wiles, Julie Cui</span></span></b></a></span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Acute onset of rapidly progressive jaundice in pt with heavy EtOH intake (&gt;40g in females or &gt;60g in males EtOH/day for &gt;6 mos, or within &lt;60 days of abstinence).</span></span></span></span></span></span>
<ul>
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none"> </li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">May present after they have quit drinking due to immunosuppressive effects of alcohol.</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">20-50% Mortality in hospitalized AH pts</span></span></span></span></span></span></li>
</ul>
</li>
</ul>
<p> </p>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">AST &gt;60, AST/ALT &gt;1.5, both values &lt;400 IU/L; TBili &gt;3.0 mg/dL, documentation of heavy EtOH use until 8 weeks prior to presentation</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Prognostication with Maddrey’s Discriminant Function: 4.6 * (PT<sub>pt</sub> – PT<sub>ctrl</sub>) + Tbili</span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Maddrey </span></span><u><span style="font-size:12.0pt"><span style="font-family:Palatino">&gt;</span></span></u><span style="font-size:12.0pt"><span style="font-family:Palatino"> 32 = poor 30d prognosis &amp; may benefit from steroids (see below)</span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">RUQ to rule out obstructive cause of jaundice</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Biopsy is not typically required but will show neutrophilic lobular inflammation, hepatocyte ballooning, steatosis, and pericellular fibrosis.</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Phosphatidylethanol (PEth) level is a biomarker of ethanol consumption over ~ 4wks; &gt;20 ng/mL can indicate chronic moderate/heavy alcohol intake </span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">A single episode consumption can result in detectable Peth for up to 12 days. Can be elevated for months with regular heavy alcohol intake. </span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">In some studies, 99% sensitive and specific for alcoholism. </span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">EtOH levels may be negative unless acutely intoxicated</span></span></span></span></span></span><br/>
		 </li>
</ul>
</li>
</ul>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Supportive Care is essential! Consult Nutrition, start High protein, high calorie diet, high dose Thiamine x 3d, Folate, MVI</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Full infection workup (CXR, UA, BCx, paracentesis) regardless of sxs</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Steroids: </span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">STOP-AH Trial (NEJM 2015) showed improved mortality at 28 days but not at 90 days in patients with Maddrey <u>&gt;</u> 32 who received steroids; the decision to treat is very nuanced and should be discussed with hepatology attending </span></span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Contraindications to steroids include: presence of infection (must rule out first</span></span> <span style="font-size:12.0pt"><span style="font-family:Palatino">including TB, uncontrolled GI bleeding, AKI w/ Cr &gt;2.5 mg/dL)</span></span></span></span></span>​​​​​​​</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Prednisolone 40mg daily for pts who meet above criteria (2018 ACG Guidelines)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">The Lille score can be used to guide continuation or d/c  of steroids after 7 d of therapy</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">NAC can be considered as adjunctive therapy to steroids and may decrease 30-day mortality, though has not demonstrated longer mortality benefit at 3 nor 6 months</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Recent analysis from STOP AH data has demonstrated that pts with neutrophil to lymphocyte ratio (NLR) 5-8 prior to steroids most likely to benefit from steroids</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Monitor on CIWA</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Psychiatry consultation as appropriate, consideration of medical therapy</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Disulfiram and naltrexone are both metabolized by the liver and can cause hepatic toxicity and therefore are not used in this population</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Baclofen has been shown to improve alcohol abstinence in pts with EtOH cirrhosis</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Acamprosate has not been studied in this population but can be considered</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Gabapentin has also demonstrated efficacy and can be given up to 1200mg for AUD</span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<p style="margin-left:50px"> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Liver transplantation</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Current VUMC policy: pts should be abstinent for no less than 3-6 months, although exceptions may be made for early liver transplant based on a very strict protocol</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Sustained Alcohol use post- Liver Transplant (SALT) score </span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Cambria Math&quot;,serif">≤</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> 6</span></span></span></span></span>
<ul>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">+4 points if &gt;10 drinks/day at initial hospitalization</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">+4 points if multiple prior rehab attempts</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">+2 points if prior alcohol related legal issues</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">+1 points if prior illicit substance abuse</span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">“Exceptions:”</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> Severe AH as first liver-decompensating event in patients who are not expected to survive to complete treatment</span></span></span></span></span>
<ul>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Presence of strong sober social support</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Absence of severe uncontrolled coexisting psychiatric disorders</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Agreement by patient and family to adhere therapy and lifelong abstinence</span></span></span></span></span></li>
</ul>
</li>
</ul>
</div>
</div>
</article>
</div>
</div>